Skip Navigation



Glycobiology Advance Access published online on June 2, 2004

Glycobiology, doi:10.1093/glycob/cwh106
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
14/12/1229    most recent
cwh106v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhang, M.
Right arrow Articles by Korber, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, M.
Right arrow Articles by Korber, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received February 13, 2004
Revised May 26, 2004
Accepted May 28, 2004

ORIGINAL ARTICLES

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes, and influenza hemagglutinin

Ming Zhang 1, Brian Gaschen 1, Wendy Blay 2, Brian Foley 1, Nancy Haigwood 2, Carla Kuiken 1, Bette Korber 3*

1 Theoretical Biology Group, Los Alamos National Laboratory, Los Alamos, NM, 87544, USA
2 Seattle Biomedical Research Institute, Seattle, Washington 98109, USA; Pathobiology Department, University of Washington, Seattle, Washington 98195, USA
3 Theoretical Biology Group, Los Alamos National Laboratory, Los Alamos, NM, 87544, USA; The Santa Fe Institute, Santa Fe, New Mexico, 875014, USA

* To whom correspondence should be addressed. E-mail: btk{at}lanl.gov.


   Abstract

Human and simian immunodeficiency viruses (HIV and SIV), influenza virus, and hepatitis C virus (HCV) have heavily glycosylated, highly variable surface proteins. Here we explore Nlinked glycosylation site (sequon) variation at the population level in these viruses, using a new web-based program developed to facilitate the sequon tracking and to define patterns (www.hiv.lanl.gov). This tool allowed rapid visualization of the two distinctive patterns of sequon variation found in HIV-1, HIV-2, and SIV CPZ. The first pattern (fixed) describes readily aligned sites that are either simply present or absent. These sites tend to be occupied by high-mannose glycans. The second pattern (shifting) refers to sites embedded in regions of extreme local length variation, and is characterized by shifts in terms of the relative position and local density of sequons; these sites tend to be populated by complex carbohydrates. HIV, with its extreme variation in number and precise location of sequons, does not have a net increase in the number of sites over time at the population level. Primate lentiviral lineages have host species dependent levels of sequon shifting, with HIV-1 in humans the most extreme. Hepatitis C E1 and E2 proteins, despite evolving extremely rapidly through point mutation, show limited sequon variation, although two shifting sites were identified. Human influenza A hemagglutinin H3 HA1 is accumulating sequons over time, but this trend is not evident in any other avian or human influenza A serotypes.

Key words: immune escape, neutralization antibody, N-linked glycosylation, variability, virus


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Microbiol. Mol. Biol. Rev.Home page
A. Onafuwa-Nuga and A. Telesnitsky
The Remarkable Frequency of Human Immunodeficiency Virus Type 1 Genetic Recombination
Microbiol. Mol. Biol. Rev., September 1, 2009; 73(3): 451 - 480.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
B. T. Korber, N. L. Letvin, and B. F. Haynes
T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces
J. Virol., September 1, 2009; 83(17): 8300 - 8314.
[Full Text] [PDF]


Home page
J. Virol.Home page
V. Peut, S. Campbell, A. Gaeguta, R. J. Center, K. Wilson, S. Alcantara, C. S. Fernandez, D. F. J. Purcell, and S. J. Kent
Balancing Reversion of Cytotoxic T-Lymphocyte and Neutralizing Antibody Escape Mutations within Human Immunodeficiency Virus Type 1 Env upon Transmission
J. Virol., September 1, 2009; 83(17): 8986 - 8992.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Cui, T. Smith, P. W. Robbins, and J. Samuelson
Darwinian selection for sites of Asn-linked glycosylation in phylogenetically disparate eukaryotes and viruses
PNAS, August 11, 2009; 106(32): 13421 - 13426.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Li, C.-F. Xu, S. Blais, Q. Wan, H.-T. Zhang, S. J. Landry, and C. E. Hioe
Proximal Glycans Outside of the Epitopes Regulate the Presentation of HIV-1 Envelope gp120 Helper Epitopes
J. Immunol., May 15, 2009; 182(10): 6369 - 6378.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Coetzer, R. Nedellec, J. Salkowitz, S. McLaughlin, Y. Liu, L. Heath, J. I. Mullins, and D. E. Mosier
Evolution of CCR5 Use before and during Coreceptor Switching
J. Virol., December 1, 2008; 82(23): 11758 - 11766.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
E. M. Bunnik, L. Pisas, A. C. van Nuenen, and H. Schuitemaker
Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection
J. Virol., August 15, 2008; 82(16): 7932 - 7941.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
C. Sugimoto, E. E. Nakayama, T. Shioda, F. Villinger, A. A. Ansari, N. Yamamoto, Y. Suzuki, Y. Nagai, and K. Mori
Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant
J. Gen. Virol., February 1, 2008; 89(2): 554 - 566.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. Elvevold, B. Smedsrod, and I. Martinez
The liver sinusoidal endothelial cell: a cell type of controversial and confusing identity
Am J Physiol Gastrointest Liver Physiol, February 1, 2008; 294(2): G391 - G400.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
C. Kuiken, P. Hraber, J. Thurmond, and K. Yusim
The hepatitis C sequence database in Los Alamos
Nucleic Acids Res., January 11, 2008; 36(suppl_1): D512 - D516.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
E. D. Quakkelaar, F. P. J. van Alphen, B. D. M. Boeser-Nunnink, A. C. van Nuenen, R. Pantophlet, and H. Schuitemaker
Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies
J. Virol., August 15, 2007; 81(16): 8533 - 8542.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
E. Falkowska, F. Kajumo, E. Garcia, J. Reinus, and T. Dragic
Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization
J. Virol., August 1, 2007; 81(15): 8072 - 8079.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
F. Helle, A. Goffard, V. Morel, G. Duverlie, J. McKeating, Z.-Y. Keck, S. Foung, F. Penin, J. Dubuisson, and C. Voisset
The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein
J. Virol., August 1, 2007; 81(15): 8101 - 8111.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
P. Delobel, M.-T. Nugeyre, M. Cazabat, C. Pasquier, B. Marchou, P. Massip, F. Barre-Sinoussi, N. Israel, and J. Izopet
Population-Based Sequencing of the V3 Region of env for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies
J. Clin. Microbiol., May 1, 2007; 45(5): 1572 - 1580.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Microbiol.Home page
B. S. Chin, S. H. Lee, G. J. Kim, M. K. Kee, S. D. Suh, and S. S. Kim
Early Identification of Seronegative Human Immunodeficiency Virus Type 1 Infection with Severe Presentation
J. Clin. Microbiol., May 1, 2007; 45(5): 1659 - 1662.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
P. Jayaraman, T. Zhu, L. Misher, D. Mohan, L. Kuller, P. Polacino, B. A. Richardson, H. Bielefeldt-Ohmann, D. Anderson, S.-L. Hu, et al.
Evidence for Persistent, Occult Infection in Neonatal Macaques following Perinatal Transmission of Simian-Human Immunodeficiency Virus SF162P3
J. Virol., January 15, 2007; 81(2): 822 - 834.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Helle, C. Wychowski, N. Vu-Dac, K. R. Gustafson, C. Voisset, and J. Dubuisson
Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans
J. Biol. Chem., September 1, 2006; 281(35): 25177 - 25183.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
B. Li, J. M. Decker, R. W. Johnson, F. Bibollet-Ruche, X. Wei, J. Mulenga, S. Allen, E. Hunter, B. H. Hahn, G. M. Shaw, et al.
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.
J. Virol., June 1, 2006; 80(11): 5211 - 5218.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
I. H. Ansari, B. Kwon, F. A. Osorio, and A. K. Pattnaik
Influence of N-Linked Glycosylation of Porcine Reproductive and Respiratory Syndrome Virus GP5 on Virus Infectivity, Antigenicity, and Ability To Induce Neutralizing Antibodies.
J. Virol., April 1, 2006; 80(8): 3994 - 4004.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
W.M. Blay, S. Gnanakaran, B. Foley, N. A. Doria-Rose, B. T. Korber, and N. L. Haigwood
Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques
J. Virol., January 15, 2006; 80(2): 999 - 1014.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
A. Pashov, S. MacLeod, R. Saha, M. Perry, T. C. VanCott, and T. Kieber-Emmons
Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12
Glycobiology, October 1, 2005; 15(10): 994 - 1001.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
N. A. Doria-Rose, G. H. Learn, A. G. Rodrigo, D. C. Nickle, F. Li, M. Mahalanabis, M. T. Hensel, S. McLaughlin, P. F. Edmonson, D. Montefiori, et al.
Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope
J. Virol., September 1, 2005; 79(17): 11214 - 11224.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
A. Goffard, N. Callens, B. Bartosch, C. Wychowski, F.-L. Cosset, C. Montpellier, and J. Dubuisson
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins
J. Virol., July 1, 2005; 79(13): 8400 - 8409.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
C. Kuiken, K. Yusim, L. Boykin, and R. Richardson
The Los Alamos hepatitis C sequence database
Bioinformatics, February 1, 2005; 21(3): 379 - 384.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.